Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 19, Number 3—March 2013

Dispatch

Lymphogranuloma Venereum in Men Screened for Pharyngeal and Rectal Infection, Germany

Karin HaarComments to Author , Sandra Dudareva-Vizule, Hilmar Wisplinghoff, Fabian Wisplinghoff, Andrea Sailer, Klaus Jansen, Birgit Henrich, and Ulrich Marcus
Author affiliations: Author affiliations: Robert Koch-Institute, Berlin, Germany (K. Haar, S. Dudareva-Vizule, A. Sailer, K. Jansen, U. Marcus); European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden (S. Dudareva-Vizule); University of Cologne, Cologne, Germany (H. Wisplinghoff); Laboratoriumsmedizin Köln–Dres. med. Wisplinghoff and Colleagues, Cologne (H. Wisplinghoff, F. Wisplinghoff); Heinrich-Heine-University, Duesseldorf, Germany (B. Henrich)

Main Article

Table 2

Characteristics of MSM patients with CT infection, by LGV status, Germany, 2009–2010*

Characteristic LGV positive, n = 19 LGV negative, n = 95 p value OR (95%CI)
Median age, y (range)
37 (27–55)
30 (19–67)
0.004

Origin n = 16 n = 80

Germany, % (no.)


87.5 (14)
80.0 (64)
0.73†
1.75 (0.34–17.33)
Reported symptoms n = 15 n = 69

None, % (no.)


53.3 (8)‡
73.9 (51)
0.13
2.48 (0.79–7.81)
Median no. male sex partners in past 6 mo (range)

All partners

9 (1–1,000) 5 (1–150) 0.11

Unprotected anal sex partners


1.5 (0–80)
1 (0–150)
0.43

Meeting place for >1 of last 3 partners, % n = 16 n = 82

The Internet

62.5 65.9 0.80 0.86 (0.29–2.62)

Bar/pub/club

50.0 26.8 0.08† 2.73 (0.91–8.15)

Sauna

6.3 13.4 0.68† 0.43 (0.01–3.43)

Sex party

18.8 3.7 0.05† 6.08 (0.71–49.10)

Pornography cinema

0 7.3 0.59† 0.60 (0.00–4.47)

Cruising

0 4.9 1.0† 0.95 (0.00–8.02)

At friends’ homes

12.5 11.0 1.0† 1.16 (0.11–6.52)

Other


6.3
7.3
1.0†
0.84 (0.02–7.81)
Location of sexual contact with last 3 partners, %§ 15 patients/33 answers 57 patients/144 answers

Germany

100.0 95.1 0.33 2.18 (0.29–∞)

Abroad


0
4.9


HIV status

% Positive

57.9 41.1 0.18 1.97 (0.73–5.36)

If positive

Median time since diagnosis, y (range)

4.5 (2.75–13.67) 2.1 (0–20.25) 0.22

HIV therapy, %

n = 8 n = 25

Combination therapy

87.5 52.0 0.11† 6.46 (0.63–312.96)

No therapy

12.5 48.0

Viral load, copies/mL, %

n = 8 n = 22

Undetectable or <1,000

100.0 54.5 0.03† 0.12 (0.00–0.94)

>1,000


0
45.5


History of CT testing and past infections
19
95


CT test ever, yes/no 9/4 27/26 0.35† 2.17 (0.52–10.73)

If yes, when

Past 3 mo

6 11

Past 6 mo

1 3

Past 12 mo


2
5


History of CT infection n = 16 n = 82

Yes, % (no.)

43.8 (7) 12.2 (10) 0.01† 5.60 (1.40–21.24)

If yes, when

Past month

2 0.57† 3.0 (0.26–35.33)

>1 mo


2
3


If history of CT infection in past month, type of current CT infection, no.

Anorectal

4 1

Urethral

0 1

*No. indicates no. persons. MSM, men who have sex with men; CT, Chlamydia trachomatis; LGV, lymphogranuloma venereum; OR, odds ratio.
†Exact logistic regression
‡3 of these patients were from 1 proctological referral practice
§Multiple answers possible.
¶Of 2 pharyngeal LGV cases, the HIV-positive patient was asymptomatic and the HIV-negative patient reported night-sweats.

Main Article

TOP